AnaptysBio CEO returns 11,000 stock options

ANAPTYSBIO, INC President and CEO Daniel Faga reported a disposition of derivative securities.

Rhea-AI Filing Summary

ANAPTYSBIO, INC President and CEO Daniel Faga reported a disposition of derivative securities. He returned 11,000 employee stock options, each exercisable for one share of common stock at $31.12 per share, to the issuer. The filing notes the option was fully vested and exercisable, and this was a non-market disposition back to the company rather than an open-market trade.

Insights

Equity compensation analyst

CEO returns 11,000 vested options to issuer in a non-market move.

President and CEO Daniel Faga reported a Disposition to issuer of 11,000 fully vested employee stock options with a $31.12 exercise price, linked to an equal number of common shares. No market trade price is shown, indicating this is an administrative equity change.

The filing shows one derivative transaction and no remaining derivative positions in this line item, suggesting a cleanup of part of his option awards rather than a purchase or sale of common stock. With no broader holding data in this excerpt, the transaction reads as routine and has limited informational value for shareholders.

Insider Trade Summary

Disposition: 11,000 shares

Disposition 1 txn

Insider Faga Daniel

Role President, CEO

Type	Security	Shares	Price	Value
Disposition	Employee Stock Option (right to buy)	11,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 11,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option is fully vested and exercisable.

Key Figures

Options disposed: 11,000 options Underlying shares: 11,000 shares Exercise price: $31.12 per share +1 more

4 metrics

Options disposed 11,000 options Employee stock options disposed to issuer

Underlying shares 11,000 shares Common stock underlying disposed options

Exercise price $31.12 per share Strike price of the employee stock options

Expiration date November 25, 2031 Option expiration for disposed grant

Key Terms

Employee Stock Option (right to buy), Disposition to issuer, fully vested and exercisable, derivative transaction

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

Disposition to issuer financial

"transaction_action: issuer disposition; transaction_code_description: Disposition to issuer"

fully vested and exercisable financial

"footnote: The stock option is fully vested and exercisable."

derivative transaction financial

"transactionSummary notes a derivativeTransactionCount of 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANAPTYSBIO (ANAB) report for Daniel Faga?

ANAPTYSBIO reported that President and CEO Daniel Faga disposed of 11,000 employee stock options back to the issuer. These options were fully vested and exercisable and related to 11,000 shares of common stock at a $31.12 exercise price per share.

Was the ANAB CEO’s Form 4/A transaction a market sale of shares?

No. The Form 4/A shows a “Disposition to issuer” of 11,000 employee stock options, not an open-market sale of common stock. The transaction price per option is reported as $0.00, indicating a non-market, administrative return of options to the company.

What were the key terms of the ANAB stock options Daniel Faga disposed of?

The disposed instruments were employee stock options to buy 11,000 ANAPTYSBIO common shares at an exercise price of $31.12 per share. A footnote states the stock option was fully vested and exercisable, with an expiration date of November 25, 2031.

How many derivative transactions does this ANAB Form 4/A amendment include?

The filing includes one derivative transaction: a disposition to the issuer of 11,000 employee stock options linked to 11,000 common shares. The transaction summary classifies this as a single derivative transaction with a dispose direction and no offsetting purchases or exercises.

Does the ANAB Form 4/A indicate ongoing derivative holdings for the CEO?

In this excerpt, the derivative summary is empty after the reported disposition, and no other derivative positions are listed. That suggests no remaining positions of this specific option award are shown here, though it does not rule out other awards outside this excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 06:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faga Daniel

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/22/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$31.12	04/20/2026		D			11,000	(1)	11/25/2031	Common Stock	11,000	$0	11,000	D

Explanation of Responses:

1. The stock option is fully vested and exercisable.

Remarks:

This amendment to Form 4, filed on April 23, 2026, updates the number of stock options to 11,000 shares of the Issuer's common stock.

	/s/ Dan Faga	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)